Pens and prospering as a manufacturer

Pens and prospering as a manufacturer

November 18, 2019

Melbourne, Victoria, Australia

Trajan Scientific and Medical (Trajan) has been featured by @AuManufacturing, highlighting Trajan's ongoing investment into the development of hemaPEN®, and other technologies to address emerging trends in healthcare.

The article outlines Trajan's collaborative approach to R&D, and success in identifying and manufacturing niche technologies for global markets.

Read the full article at @AUManufacturing - Pens and prospering as a manufacturer.

More information
hemaPEN
About us
@AuManufacturing

Media contact information
Trajan Scientific and Medical
Tel: +44 (0) 1908 568 844
media@trajanscimed.com

The hemaPEN® is a device supplied for research purposes only. This device is not for therapeutic or diagnostic use.




Also in News

Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst
Advantages of hemaPEN blood microsampling validated for therapeutic drug monitoring in RSC’s Analyst

September 07, 2020

Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.

Read More

European patent for Trajan’s hemaPEN
European patent for Trajan’s hemaPEN

July 13, 2020

Trajan Scientific and Medical is proud to advise that the European Patent Office will be granting a patent for hemaPEN® as a liquid collection device in Belgium, France, Germany, Ireland, Luxembourg, Monaco, Switzerland, Liechtenstein and the United Kingdom. Extensions are being sought across the remainder of Europe.

Read More

US FDA listing of Trajan’s hemaPEN blood microsampling device
US FDA listing of Trajan’s hemaPEN blood microsampling device

July 02, 2020

Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.

Read More